Celgene Could Dethrone Biogen in Multiple Sclerosis

In July 2015, Celgene made headlines with its $7.2 billion acquisition of Receptos -- mainly in order to get its hands on Receptos' lead autoimmune candidate, ozanimod. While estimates vary, Celgene management has guided to peak sales of $4 billion to $6 billion annually -- which would make this a very good deal for Celgene. However, current autoimmune juggernaut Biogen (NASDAQ:BIIB) may have a trick up its sleeve that could blow ozanimod out of the water.